ArticleOncotarget2018
Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.
Roberta Fenoglio et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this paperpooled itcites it